313 related articles for article (PubMed ID: 18559761)
1. Prospective multicenter study of pegylated liposomal doxorubicin treatment in patients with advanced or refractory mycosis fungoides or Sézary syndrome.
Quereux G; Marques S; Nguyen JM; Bedane C; D'incan M; Dereure O; Puzenat E; Claudy A; Martin L; Joly P; Delaunay M; Beylot-Barry M; Vabres P; Celerier P; Sasolas B; Grange F; Khammari A; Dreno B
Arch Dermatol; 2008 Jun; 144(6):727-33. PubMed ID: 18559761
[TBL] [Abstract][Full Text] [Related]
2. Prospective international multicenter phase II trial of intravenous pegylated liposomal doxorubicin monochemotherapy in patients with stage IIB, IVA, or IVB advanced mycosis fungoides: final results from EORTC 21012.
Dummer R; Quaglino P; Becker JC; Hasan B; Karrasch M; Whittaker S; Morris S; Weichenthal M; Stadler R; Bagot M; Cozzio A; Bernengo MG; Knobler R
J Clin Oncol; 2012 Nov; 30(33):4091-7. PubMed ID: 23045580
[TBL] [Abstract][Full Text] [Related]
3. Multicenter study of pegylated liposomal doxorubicin in patients with cutaneous T-cell lymphoma.
Wollina U; Dummer R; Brockmeyer NH; Konrad H; Busch JO; Kaatz M; Knopf B; Koch HJ; Hauschild A
Cancer; 2003 Sep; 98(5):993-1001. PubMed ID: 12942567
[TBL] [Abstract][Full Text] [Related]
4. Bexarotene therapy for mycosis fungoides and Sézary syndrome.
Abbott RA; Whittaker SJ; Morris SL; Russell-Jones R; Hung T; Bashir SJ; Scarisbrick JJ
Br J Dermatol; 2009 Jun; 160(6):1299-307. PubMed ID: 19222457
[TBL] [Abstract][Full Text] [Related]
5. Pegylated liposomal doxorubicin (CAELYX) in patients with advanced ovarian cancer: results of a German multicenter observational study.
Sehouli J; Camara O; Schmidt M; Mahner S; Seipelt G; Otremba B; Schmalfeldt B; Tesch H; Lorenz-Schlüter C; Oskay-Ozcelik G;
Cancer Chemother Pharmacol; 2009 Aug; 64(3):585-91. PubMed ID: 19156414
[TBL] [Abstract][Full Text] [Related]
6. Pegylated liposomal doxorubicin as second-line therapy in the treatment of patients with advanced classic Kaposi sarcoma: a retrospective study.
Di Lorenzo G; Di Trolio R; Montesarchio V; Palmieri G; Nappa P; Delfino M; De Placido S; Dezube BJ
Cancer; 2008 Mar; 112(5):1147-52. PubMed ID: 18098221
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the efficacy of the combination of oral bexarotene and methotrexate for the treatment of early stage treatment-refractory cutaneous T-cell lymphoma.
Kannangara AP; Levitan D; Fleischer AB
J Dermatolog Treat; 2009; 20(3):169-76. PubMed ID: 19016373
[TBL] [Abstract][Full Text] [Related]
8. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma.
Olsen EA; Kim YH; Kuzel TM; Pacheco TR; Foss FM; Parker S; Frankel SR; Chen C; Ricker JL; Arduino JM; Duvic M
J Clin Oncol; 2007 Jul; 25(21):3109-15. PubMed ID: 17577020
[TBL] [Abstract][Full Text] [Related]
9. Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma.
Duvic M; Martin AG; Kim Y; Olsen E; Wood GS; Crowley CA; Yocum RC;
Arch Dermatol; 2001 May; 137(5):581-93. PubMed ID: 11346336
[TBL] [Abstract][Full Text] [Related]
10. Thalidomide-dexamethasone plus pegylated liposomal doxorubicin vs. thalidomide-dexamethasone: a case-matched study in advanced multiple myeloma.
Offidani M; Bringhen S; Corvatta L; Falco P; Marconi M; Avonto I; Piersantelli MN; Polloni C; Boccadoro M; Leoni P; Palumbo A
Eur J Haematol; 2007 Apr; 78(4):297-302. PubMed ID: 17286608
[TBL] [Abstract][Full Text] [Related]
11. Analysis of long-term outcomes of combined modality therapy for cutaneous T-cell lymphoma.
Duvic M; Apisarnthanarax N; Cohen DS; Smith TL; Ha CS; Kurzrock R
J Am Acad Dermatol; 2003 Jul; 49(1):35-49. PubMed ID: 12833006
[TBL] [Abstract][Full Text] [Related]
12. Pegylated liposomal doxorubicin-efficacy in patients with recurrent high-grade glioma.
Hau P; Fabel K; Baumgart U; Rümmele P; Grauer O; Bock A; Dietmaier C; Dietmaier W; Dietrich J; Dudel C; Hübner F; Jauch T; Drechsel E; Kleiter I; Wismeth C; Zellner A; Brawanski A; Steinbrecher A; Marienhagen J; Bogdahn U
Cancer; 2004 Mar; 100(6):1199-207. PubMed ID: 15022287
[TBL] [Abstract][Full Text] [Related]
13. Long-term prognosis of HIV-infected patients with Kaposi sarcoma treated with pegylated liposomal doxorubicin.
Martín-Carbonero L; Palacios R; Valencia E; Saballs P; Sirera G; Santos I; Baldobí F; Alegre M; Goyenechea A; Pedreira J; González del Castillo J; Martínez-Lacasa J; Ocampo A; Alsina M; Santos J; Podzamczer D; González-Lahoz J;
Clin Infect Dis; 2008 Aug; 47(3):410-7. PubMed ID: 18582203
[TBL] [Abstract][Full Text] [Related]
14. Pegylated Liposomal Doxorubicin HCL (Caelyx) in combination with Sandostatin LAR as salvage therapy in patients with small-cell lung cancer.
Charpidou A; Hatzidarellis EP; Alamara C; Dilana K; Pantazopoulos K; Kotteas E; Georgatou N; Syrigos KN
In Vivo; 2006; 20(4):553-7. PubMed ID: 16900789
[TBL] [Abstract][Full Text] [Related]
15. Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma.
Whittaker SJ; Demierre MF; Kim EJ; Rook AH; Lerner A; Duvic M; Scarisbrick J; Reddy S; Robak T; Becker JC; Samtsov A; McCulloch W; Kim YH
J Clin Oncol; 2010 Oct; 28(29):4485-91. PubMed ID: 20697094
[TBL] [Abstract][Full Text] [Related]
16. Molecular staging of lymph nodes from 60 patients with mycosis fungoides and Sézary syndrome: correlation with histopathology and outcome suggests prognostic relevance in mycosis fungoides.
Fraser-Andrews EA; Mitchell T; Ferreira S; Seed PT; Russell-Jones R; Calonje E; Whittaker SJ
Br J Dermatol; 2006 Oct; 155(4):756-62. PubMed ID: 16965425
[TBL] [Abstract][Full Text] [Related]
17. Palliative total skin electron beam therapy (TSEBT) for advanced cutaneous T-cell lymphoma.
Funk A; Hensley F; Krempien R; Neuhof D; Van Kampen M; Treiber M; Roeder F; Timke C; Herfarth K; Helmbold P; Debus J; Bischof M
Eur J Dermatol; 2008; 18(3):308-12. PubMed ID: 18474461
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of pegylated liposomal doxorubicin in primary cutaneous B-cell lymphomas and comparison with the commonly used therapies.
Pulini S; Rupoli S; Goteri G; Pimpinelli N; Alterini R; Bettacchi A; Mulattieri S; Picardi P; Tassetti A; Scortechini AR; Fioritoni G; Leoni P
Eur J Haematol; 2009 Mar; 82(3):184-93. PubMed ID: 19215609
[TBL] [Abstract][Full Text] [Related]
19. Treatment of early-stage mycosis fungoides with twice-weekly applications of mechlorethamine and topical corticosteroids: a prospective study.
de Quatrebarbes J; Estève E; Bagot M; Bernard P; Beylot-Barry M; Delaunay M; D'Incan M; Souteyrand P; Vaillant L; Cordel N; Courville P; Joly P
Arch Dermatol; 2005 Sep; 141(9):1117-20. PubMed ID: 16172308
[TBL] [Abstract][Full Text] [Related]
20. FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma.
Mann BS; Johnson JR; Cohen MH; Justice R; Pazdur R
Oncologist; 2007 Oct; 12(10):1247-52. PubMed ID: 17962618
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
